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Abstract
Introduction—Healthcare provider recommendations are critical for human papillomavirus 
(HPV) vaccine uptake. We sought to describe providers' HPV vaccine recommendation practices 
and explore their perceptions of parental hesitancy.
Method—A statewide sample (n=575) of Minnesota healthcare providers (20% pediatricians, 
47% family medicine physicians, 33% nurse practitioners) completed our online survey in April 
2013.
Results—Only 76% of healthcare providers reported routinely recommending HPV vaccine for 
girls ages 11-12, and far fewer (46%) did so for boys (p<.001). A majority of providers reported 
asking questions about parents' concerns (74%), but many lacked time to probe reasons (47%) or 
felt that they could not change parents' minds (55%). Higher levels of self-efficacy and outcome 
expectations were associated with routine recommendations (p<.05).
Discussion—Findings suggest that providers' perceptions of hesitancy may discourage them 
from routinely recommending HPV vaccine. Improving providers' self-efficacy to address 
hesitancy may be important for improving vaccination rates.
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Human papillomavirus (HPV) vaccine is a cost-effective way to confer protection against 
genital warts and several types of cancer, and yet it remains one of the most underused 
vaccines in the United States. National guidelines have recommended routine administration 
of HPV vaccine to 11-12 year old females since 2006 (Markowitz et al., 2007). In October 
2011, this recommendation was extended to males (Dunne et al., 2011), strengthening the 
previous “permissive recommendation” that HPV vaccine received in 2009 (Centers for 
Disease Control and Prevention (CDC), 2010). Despite these recommendations, estimates 
from 2012 indicate that only 33% of adolescent girls and 7% of boys have completed the 3-
dose HPV vaccine series (Curtis et al., 2013). By contrast, two other vaccines introduced to 
adolescents' immunization schedule in the same time period have made steady progress 
toward the Healthy People 2020 goal of 80% coverage (U.S. Department of Health and 
Human Services). In light of disappointing uptake, research to understand the unique 
challenges of HPV vaccination has gained prominence.
Of the many factors that influence HPV vaccination, the role of healthcare providers is 
perhaps the most important. Receiving a providers' recommendation is one of the strongest 
and most consistent predictors of HPV vaccination (Allen et al., 2010; Reiter, Brewer, 
Gottlieb, McRee, & Smith, 2009; Rosenthal et al., 2011; Ylitalo, Lee, & Mehta, 2013). 
Despite evidence suggesting that they are highly influential, healthcare providers often fail 
to recommend the vaccine according to guidelines (Vadaparampil et al., 2011) Parental 
reports suggest that only about half of female and 1 in 10 male adolescents have ever 
received a recommendation for HPV vaccine (Darden et al., 2013; Reiter, Gilkey, & Brewer, 
2013) and lack of provider recommendation is one of the most common reasons parents give 
for not getting the vaccine for their child (Dorell, Yankey, & Strasser, 2011; Reiter, Katz, & 
Paskett, 2013).
Healthcare providers face a number of barriers to recommending HPV vaccine, some of 
which are interpersonal in nature. For example, some providers express difficulty discussing 
sexual health issues that may attend HPV vaccination, particularly with younger adolescents 
in the target age range for vaccination (Daley et al., 2010; Vadaparampil et al., 2011). 
Others perceive parents as being opposed to the vaccine and are reluctant to strongly 
recommend the vaccine due to concerns about initiating time-consuming or confrontational 
debates (Daley et al., 2010; Hughes, Jones, Feemster, & Fiks, 2011). Indeed, prior research 
suggests that vaccine refusal and delay is common among parents of adolescents (Daley et 
al., 2010; Gilkey, McRee, & Brewer, 2013), although relatively little is known about how 
providers understand or address parental hesitancy specific to HPV vaccine. We sought to 
describe healthcare providers' HPV vaccine recommendation practices and to explore their 
perceptions of, and approaches to addressing, HPV vaccine hesitancy among parents of 11- 
to 12-year-old youth.
Methods
We surveyed a statewide sample of physicians and nurse practitioners who provide 
preventive care to preteens and adolescents ages 11-17 years. We identified potential 
participants through publically available lists provided by the Minnesota Boards of Medical 
Practice and of Nursing. From these lists, we sampled healthcare providers in pediatric and 
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family medicine specialties. Because our sampling frame included many providers who 
potentially did not meet study criteria (e.g., neonatal specialists), the survey used a screener 
question to limit respondents to those who provided preventive care to patients ages 11-17 
years.
In April 2013, we invited 3,923 healthcare providers to participate in the study. A total of 
615 respondents provided informed consent, and took our cross-sectional, online survey 
(adjusted response rate based on AAPOR formula 4: 28%) (American Association for Public 
Opinion Research, 2009). Among those who were confirmed to be eligible based on survey 
screening questions, the cooperation rate was 86% (i.e., the proportion of eligible providers 
contacted who completed the survey; AAPOR, 2009). Study data were collected and 
managed using REDCap (Research Electronic Data Capture) tools hosted at the University 
of Minnesota (Harris et al., 2009). Respondents received a survey invitation describing the 
study's purpose and providing a link to the survey; non-respondents received up to 3 
reminder emails. No incentives were provided for participation. The Institutional Review 
Board at the University of Minnesota approved the study.
Measures
We developed items based on the literature and our previous research with parents 
(Dempsey, Abraham, Dalton, & Ruffin, 2009; Gilkey et al., 2013; Hughes et al., 2011; 
Kempe et al., 2011; Opel et al., 2012; Vadaparampil et al., 2011). We conducted cognitive 
interviews with 5 healthcare providers to identify potential sources of response error and 
ensure the clarity of new survey items (Willis, 2005). We used findings from cognitive 
interviews to refine and improve survey items before fielding the full survey. Questions 
specified the 11-12 year old age group to align with HPV vaccination guidelines from the 
Advisory Committee on Immunization Practices (ACIP) (Centers for Disease Control and 
Prevention (CDC), 2010; Dunne et al., 2011; Markowitz et al., 2007).
The survey assessed providers' HPV vaccine recommendation practices with 3 parallel items 
asked separately about girls and boys. The first question asked how often providers 
recommended HPV vaccine as a part of routine care for 11-12 year olds. We categorized 
responses for this analysis as “most of the time” (defined as “more than 75% of the time”) 
vs. less often to reflect ACIP guidelines for routine administration (Centers for Disease 
Control and Prevention (CDC), 2010; Dunne et al., 2011; Markowitz et al., 2007) and to 
address the skewed nature of the distributions. Based on our formative qualitative research, 
the survey also included two statements assessing the strength of providers' HPV vaccine 
recommendations.
Following text instructing respondents to think about the times during the last year they 
recommended HPV vaccine to parents of 11-12 year olds patients, providers indicated how 
often they encountered different types of parental reactions (5 items) and rated how much 
potential concerns contributed to parents' decisions to delay or refuse HPV vaccine for their 
child (12 items). The survey then assessed providers' responses to parental HPV vaccine 
hesitancy (6 items), self-efficacy (i.e., confidence in their ability to address parents' 
concerns; 4 items), outcome expectations (i.e., expectations that their discussions with 
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parents will lead to vaccination; 3 items) (Bandura, 1986), and perceptions of potential 
strategies and tools for counseling HPV-vaccine hesitant parents (8 items).
Respondents also provided information about sociodemographic and practice characteristics 
including: age, sex, training specialty, year finished clinical training, practice type and 
location, and proportion of patients 11-17 years old.
Analyses
Of the 615 total respondents, the analytic sample for the present analysis includes 575 
respondents who answered questions about HPV vaccine recommendations and parental 
hesitancy. We used chi-square analyses to test for differences in recommendation practices 
by provider type (i.e., pediatrician, family medicine physician, or nurse practitioner). We 
assessed associations between routinely recommending HPV vaccine and providers: 
perceptions of parents' reactions, responses to hesitancy, self-efficacy to address parental 
concerns, and outcomes expectations using logistic regression models controlling for 
provider type. We conducted all analyses in Stata SE version 10.0 (Statacorp, College 
Station, TX) using two-tailed tests and a critical alpha of .05.
Results
Respondent characteristics
The average age of respondents was 48 years (Table 1). Most respondents were female 
(72%). About half were family medicine physicians (47%) and one-third were nurse 
practitioners (33%). Most respondents worked in either private practice (32%) or a practice 
network (31%) and served patient populations comprised of more than 10% adolescents 
(60%). Respondents included in the analysis did not differ from those excluded with regards 
to any of the assessed socio-demographic and practice characteristics (all p>.05).
HPV vaccine recommendation practices
About three-quarters of healthcare providers (76%) reported recommending HPV 
vaccination to girls ages 11-12 as a part of their routine care “most of the time.” Providers 
routinely recommended the vaccine for boys less often than for girls, with fewer than half 
(46%) reporting that they do so “most of the time” (χ2=152.49, p<.001). As shown in Figure 
1, more pediatricians routinely recommended HPV vaccine for boys than did both family 
medicine physicians and nurse practitioners (67% vs. 42% and 41% respectively, p<.001). 
HPV vaccine recommendations for girls did not differ by provider type (p=.06).
Many providers “somewhat” or “strongly” agreed that they recommend HPV vaccine as 
strongly as they do other adolescent vaccines (for girls, 75%; for boys, 64%). However, 
most also agreed that they prefer to offer HPV vaccine as an optional vaccine for girls (62%) 
or for boys (69%) ages 11-12.
Parental reactions to HPV vaccine recommendations for 11-12 year olds
One-third of providers (33%) reported that parents frequently (i.e., “often” or “most of the 
time”) accept HPV vaccine recommendations without question, while half (51%) reported 
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that parents frequently ask to delay vaccination (Table 2). One-fifth (18%) indicated that 
parents frequently respond with concern about HPV vaccine, and 12% reported that parents 
frequently refuse to get HPV vaccine for their child. Providers had lower odds of 
recommending HPV vaccine to 11-12 years olds “most of the time” if they reported that 
parents responded more frequently with requests to delay vaccination or if they more 
frequently refused HPV vaccine for their child. Providers who reported that parents more 
frequently accepted HPV vaccine without question had higher odds of recommending it 
“most of the time” (all p<.05). Parental reactions of anger or concern about HPV vaccine 
were not statistically associated with providers' HPV vaccine recommendation practices.
In terms of reasons for HPV vaccine delay or refusal, most providers perceived factors that 
contributed “some” or “a lot” to parents' decisions to include the belief that their child is not 
sexually active (79%) or is unlikely to get an HPV-related disease (63%), as well as parental 
discomfort talking with their child about sex (55%; Table 3). Providers perceived that 
concerns about short-term side effects, cost, or effectiveness contributed little to parents' 
decisions to delay or refuse HPV vaccination for their child.
Provider responses to parental HPV vaccine hesitancy
Most providers reported frequently (i.e., “often” or “most of the time”) responding to 
parental HPV vaccine hesitancy by offering reassurance that the vaccine is safe (90%), 
giving standard written information (such as the Centers for Disease Control and 
Prevention's Vaccine Information Sheets; 83%), or asking questions to explore parents' 
concerns (74%; Table 2). All assessed responses to parental HPV vaccine hesitancy were 
positively associated with recommending HPV vaccine to 11-12 year old girls or boys “most 
of the time” (all p<.001) with the exception of suggesting that parents delay vaccination 
until a future visit which was associated with lower odds of routine recommendation.
Most healthcare providers felt confident that they could address parental concerns about 
sexual disinhibition (86% “somewhat agreed” or “strongly agreed”; Table 4) and HPV 
vaccine for boys (88%). However, nearly half indicated that they did not have enough time 
during visits to probe parents' reasons for vaccine hesitancy (47%). While the vast majority 
of providers felt that they are influential in parents' decisions about whether to get HPV 
vaccine for their child (91%), two-thirds (55%) felt that there was not much they could say 
to change the minds of parents who parents wish to delay or refuse vaccination. All assessed 
self-efficacy and outcome expectations beliefs were positively associated with routinely 
recommending HPV vaccine to 11-12 year olds (all p<.05) with the exception of believing 
that there is not much they can say to change parents' minds which was not statistically 
significant for either girls or boys.
Tools and strategies for counseling HPV vaccine-hesitant parents
The strategies and tools that providers perceived would be most helpful (i.e., “a lot” or 
“somewhat”) for counseling parents who are hesitant to get their adolescent children 
vaccinated against HPV were: information tailored to specific parent concerns (74%) or to 
parents' cultural background (68%), and providing information about HPV vaccine to 
parents prior to the clinical visit (72%; Table 3). Over half of providers also felt that it 
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would be helpful to have a screening tool to identify specific parental concerns (58%) or a 
discussion guide (57%).
Discussion
Despite national guidelines for routine HPV vaccination of 11-12 year-olds, nearly 1 out of 
4 healthcare providers in our statewide sample indicated that they are not routinely 
recommending the vaccine for girls, and more than half reported not doing so for boys even 
18-months after the release of guidelines recommending routine vaccination of males. While 
such gender-based differences are not surprising given the initial roll-out of the vaccine for 
girls only, they are concerning. If trends in vaccine uptake among females provide an 
indication of trajectories for males, vaccine coverage may increase, but remain below 
targets. Furthermore, our findings suggest that recommendations providers do deliver may 
be ambiguous; most respondents reported preferring to offer the vaccine as optional, and a 
significant minority indicated that they do not recommend HPV vaccine as strongly as other 
adolescent vaccines. As receiving a provider's recommendation is one of the strongest 
correlates of HPV vaccination, our findings lend support to a growing body of literature that 
highlights the importance of increasing the frequency and quality of recommendations 
(Allen et al., 2010; Reiter et al., 2009; Rosenthal et al., 2011; Vadaparampil et al., 2011). 
Improving HPV vaccine recommendations may be especially important for raising coverage 
among boys since parents are less likely to know that the vaccine is available for their sons 
(Gilkey, Moss, McRee, & Brewer, 2012).
Healthcare providers in our sample perceived parental HPV vaccine hesitancy to be 
common; about half of respondents reported that parents frequently request to delay or 
sometimes wish to refuse HPV vaccination. The high frequency of perceived hesitancy is 
concerning and, in aggregate, may constitute a substantial burden for providers, who 
experience vaccine hesitancy as a frustrating and time-consuming problem (Kempe et al., 
2011). Importantly, our findings suggest that perceptions of parental hesitancy may 
discourage providers from delivering recommendations according to guidelines. This is 
particularly concerning as recent research suggests that providers are over-estimating 
parental concerns with regard to HPV and flu vaccines (Healy, Montesinos, & Middleman, 
2014). Providers may be reassured to learn that parental concerns about adolescent vaccines 
are not as frequent or severe as they suspect. Indeed, consistent with previous findings on 
HPV vaccine recommendations for females (Daley et al., 2010), providers in this sample 
who reported more frequently encountering parental responses of refusal or delay were less 
likely to routinely recommend HPV vaccination to either female or male adolescents.
Our findings suggest that providers' self-efficacy to address parental HPV vaccine hesitancy 
and their outcome expectations may also influence their recommendation practices. We 
found that respondents with lower levels of confidence in addressing concerns and who felt 
they were not influential or able to convince parents to get the vaccine were less likely to 
routinely recommended HPV vaccination to either males or females. Although the cross-
sectional nature of our data preclude drawing conclusions about the directionality of this 
relationship, prior research supports the hypothesis that providers' self-efficacy and outcome 
expectations are associated with adherence to clinical guidelines (Cabana et al., 1999). 
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Improving providers' self-efficacy to address parental concerns may be important for 
supporting recommendation practices and ultimately improving HPV vaccine uptake in the 
target age group.
Respondents in our sample perceived parents' association between HPV vaccine and sexual 
activity to be an especially common source of hesitancy. Provider training or other tools 
may be particularly helpful if aimed at helping to convey that HPV vaccination is most 
beneficial before the onset of sexual activity and that HPV is highly prevalent. In addition, 
identifying ways of discussing HPV vaccine in a manner that helps providers navigate 
discomfort with discussing sexual activity may also be important, as these topics may not be 
adequately addressed in vaccine conversations (Perkins & Clark, 2013) and providers may 
be less likely to recommend HPV vaccine if they feel they must broach sexuality in the 
context of HPV vaccine discussions (Daley et al., 2010). Our finding that very few 
healthcare providers perceived that parents react to HPV vaccine recommendations by being 
offended or angry may give providers more confidence in initiating these discussions.
To effectively communicate with vaccine-hesitant parents, healthcare providers need to 
understand parents' specific concerns. However, a quarter of providers in our sample 
reported that they only sometimes or rarely ask questions to explore parents' reasons, and 
many indicated lacking time to address parental hesitancy. Effective and efficient ways of 
assessing and addressing parents' vaccine concerns are needed, and many providers in this 
study indicated that a screening questionnaire to identify parental concerns would be helpful 
for counseling HPV-vaccine hesitant parents. Research suggests that such tools can be a 
reliable and valid way to identify parents who are hesitant to get their young children 
vaccinated (Opel et al., 2011), though to date, no such screener exists for vaccines in 
adolescent platform. Most providers also indicated that written information that addresses 
specific concerns would be helpful. Such targeted information may increase the relevance of 
information provided to parents (Kreuter & Wray, 2003) and could be an effective and low-
burden supplement to the standard written information that the vast majority already offers 
parents. Beyond didactic information which alone is unlikely to change parents' parents' 
intentions to vaccinate (Dempsey, Zimet, Davis, & Koutsky, 2006; Lechuga, Swain, & 
Weinhardt, 2012), providers in our sample were also interested in an interactive decision aid 
(Fiks et al., 2013) which could assist parents in making decisions about HPV vaccine before 
or during a clinical visit (e.g., in the waiting room). Future intervention research should 
explore these opportunities; available tools for early childhood immunization may offer a 
starting point for this work.
Study findings highlight differences in HPV vaccine recommendation practices based on 
provider specialty. In contrast to previous research (Daley et al., 2010; Weiss, Zimet, 
Rosenthal, Brenneman, & Klein, 2010), we did not find provider type differences in HPV 
vaccine recommendations for girls. However, we did note differences in recommendations 
for boys with fewer family medicine physicians and nurse practitioners routinely 
recommending the vaccine n than pediatricians. These between-type differences may reflect 
the populations served by different types of providers. For example, in our sample, family 
medicine physicians and nurse practitioners reported serving fewer adolescents than 
pediatricians. While it is possible that pediatric and family nurse practitioners also differ in 
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their HPV vaccine recommendation practices, our data did not allow us to differentiate nurse 
practitioners by practice specialty. Future research in this area should examine differences 
among nurse practitioners. Efforts to improve HPV should continue to reach out to 
healthcare professionals beyond pediatricians to include all providers who provide 
preventive care to adolescent patients.
Strengths and limitations
Study strengths include a large, statewide sample and diversity of respondents with regard to 
specialty. Limitations include a cross-sectional design and a modest response rate which 
may lead to nonresponse bias and limits the generalizability of our findings; however the 
cooperation rate among confirmed eligible providers was quite high. While our study is 
strengthened by a focus on the target age group for HPV vaccination, previous research 
consistently finds that providers' recommendation intentions and practices vary by patient 
age (Allison et al., 2013; Daley et al., 2010; Kahn et al., 2005; Weiss et al., 2010). Future 
research should investigate HPV vaccine hesitancy among parents of older adolescents as 
well as among adolescent patients themselves. Our data are based on providers' self-report 
which may be subject to recall and social desirability bias; however, responses were 
anonymous, reducing this likelihood. Findings regarding nurse practitioners may be skewed 
because we were not able to distinguish between pediatric and family nurse practitioners in 
the present study. Finally, since we surveyed healthcare providers from a single state, the 
generalizability of the findings to other populations in other regions will need to be 
established.
Conclusion
This study offers new information on healthcare providers' reported HPV vaccine 
recommendation practices for boys post-licensure and provides insight into healthcare 
providers' experiences with parental vaccine hesitancy. Increasing HPV vaccine coverage, 
particularly in the target age range of young adolescents, is a national health priority (U.S. 
Department of Health and Human Services). However, the high proportion of providers in 
our study who do not routinely recommend HPV vaccine to 11-12 year olds as per national 
guidelines, combined with providers' perceptions of widespread parental concerns about the 
vaccine, point to the importance of developing tools and strategies that can enable providers 
to effectively address HPV vaccine hesitancy (Sadaf, Richards, Glanz, Salmon, & Omer, 
2013). Intervention research is needed to speed adoption of recommended HPV vaccination 
practices among providers and ultimately increase uptake among young adolescents. The 
results of this study highlight potential targets to improve healthcare providers' 
recommendations and tools for more effectively counseling vaccine-hesitant parents that can 
inform future intervention.
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• Despite guidelines, many healthcare providers are not routinely recommending 
HPV vaccine for 11-12 year old girls or boys.
• Healthcare providers perceive parental HPV vaccine hesitancy to be common.
• Perceptions of hesitancy may discourage providers from routinely 
recommending HPV vaccine.
• Providers' self-efficacy to address hesitancy may be important for improving 
vaccine uptake.
• Findings highlight potential tools for more effectively counseling vaccine-
hesitant parents.
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Percentage of providers who recommend HPV vaccine to adolescents ages 11-12 as part of 
their routine care more than 75% of the time, by patient sex. Bars=95% confidence intervals.
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Age in years, mean (SD)a 48 (10)
Sex
 Female 413 (72)
 Male 162 (28)
Training specialty
 Pediatrician 115 (20)
 Family medicine physician 269 (47)
 Nurse practitioner 191 (33)
Year finished residency or clinical training
 1989 or earlier 147 (26)
 1990-1999 183 (32)
 2000-2009 157 (27)
 2010 or later 64 (11)
 Missing 24 (4)
Practice characteristics
Practice type
 Private, independent practice 186 (32)
 Practice network / HMO 179 (31)
 Hospital or medical center 119 (21)
 Other 91 (16)
Practice location
 Urban 162 (28)
 Suburban 240 (42)
 Rural 172 (30)
Proportion of adolescent patients (11-17 yrs)
 ≤ 10% 228 (40)
 11-25% 209 (36)
 > 25% 138 (24)
Note. Percentages may not sum to 100 due to rounding.
a
Range=26-82 years
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Table 3
Providers' perception of reasons for parental HPV-vaccine hesitancy and helpfulness of 
potential tools
A lot % Some % A little % Not at all %
Perceived reasons for parental delay or refusal of HPV vaccine for their child
 Belief that child is not sexually active 43 36 15 6
 Belief that child is unlikely to get HPV-related disease 24 39 28 9
 Discomfort talking with their child about sex 14 41 34 12
 Concerns about vaccine in general 8 37 49 6
 Concern about getting multiple vaccines 9 34 43 15
 Concern about long-term complications 7 28 42 24
 Belief that HPV is not severe 5 28 32 36
 Concern about short-term side effects (e.g., fever, pain) 2 20 46 33
 Concern about cost 4 17 34 45
 Child refused the vaccine 2 15 37 46
 Child was sick at the time of the visit 2 8 41 49
 Belief that HPV vaccine is not very effective 1 10 30 59
Helpfulness of potential tools for counseling HPV-vaccine hesitant parents
 Information sheets or brochures tailored to specific parent concerns 34 40 19 6
 Providing information about HPV vaccine to parents before the clinical visit 33 39 21 7
 Written information for parents that is tailored to their cultural background 34 34 23 9
 A screening questionnaire to identify specific parent concerns 20 38 27 14
 A discussion guide or script for health care professionals 16 41 28 15
 More attractive/accessible version of standard Vaccine Information Sheets 18 32 32 19
 Interactive decision aids (e.g., written materials, computer-assisted guide) that help 
parents make HPV vaccine decisions consistent with their values
13 31 40 17
 Providing information for parents and adolescents separately 11 33 32 25
Note. Presented in descending order by variable means. Percentages may not sum to 100 due to rounding.
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